pharmaphorum1h
J&J adds to IL-23 options in Crohn's after FDA approval
Johnson & Johnson's IL-23 inhibitor Tremfya has been approved by the FDA as a treatment for Crohn's disease, becoming the ...
The Pharma Letter1h
FDA nod for Tremfya as J&J builds on Stelara transition
US pharma major Johnson & Johnson (NYSE: JNJ) has won US approval for Tremfya (guselkumab) in the treatment of adults with ...
FDA approves Johnson & Johnson’s Tremfya to treat Crohn’s disease
Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya ...
The Chosun Ilbo on MSN10h
Korean biotech firms race into $26 billion U.S. biosimilar market
South Korean biotech firms are targeting the $26 billion biosimilar market opening up as patents expire on more than 10 ...
Fierce Pharma12h
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
JD Supra20h
Celltrion Launches STEQEYMA® (ustekinumab-stba) in the United States
Celltrion announced the commercial launch of STEQEYMA® (ustekinumab-stba), a biosimilar of Janssen’s STELARA® (ustekinumab), in the United States. As we previously reported, the biosimilar was ...
Managed Healthcare Executive21h
Optum Rx Changes How Pharmacies Are Reimbursed
The new cost-based program leverages multiple available industry data sources, such as NADAC and PAC, to inform reimbursement ...